JPH0573398B2 - - Google Patents
Info
- Publication number
- JPH0573398B2 JPH0573398B2 JP60017452A JP1745285A JPH0573398B2 JP H0573398 B2 JPH0573398 B2 JP H0573398B2 JP 60017452 A JP60017452 A JP 60017452A JP 1745285 A JP1745285 A JP 1745285A JP H0573398 B2 JPH0573398 B2 JP H0573398B2
- Authority
- JP
- Japan
- Prior art keywords
- substrate
- reagent
- acetyl
- present
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 239000000758 substrate Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims description 8
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 6
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 6
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 6
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000003595 spectral effect Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- -1 For example Chemical compound 0.000 description 1
- VLBWGEJJANMXEB-UHFFFAOYSA-N 2,3,5,6-tetrabromo-4-nitrophenol Chemical compound OC1=C(Br)C(Br)=C([N+]([O-])=O)C(Br)=C1Br VLBWGEJJANMXEB-UHFFFAOYSA-N 0.000 description 1
- OSAJZHUCWQMEDB-UHFFFAOYSA-N 2,3,6-tribromo-4-nitrophenol Chemical compound OC1=C(Br)C=C([N+]([O-])=O)C(Br)=C1Br OSAJZHUCWQMEDB-UHFFFAOYSA-N 0.000 description 1
- UAXQXSVCGHEVMI-UHFFFAOYSA-N 2,3,6-trichloro-4-nitrophenol Chemical compound OC1=C(Cl)C=C([N+]([O-])=O)C(Cl)=C1Cl UAXQXSVCGHEVMI-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- UWEZBKLLMKVIPI-UHFFFAOYSA-N 2,5-dinitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1[N+]([O-])=O UWEZBKLLMKVIPI-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- OMRLTNCLYHKQCK-DHGKCCLASA-N 4-nitrophenyl N-acetyl-beta-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-DHGKCCLASA-N 0.000 description 1
- DCIPFSYBGTWYCR-UHFFFAOYSA-N 5847-59-6 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1Br DCIPFSYBGTWYCR-UHFFFAOYSA-N 0.000 description 1
- PXSGFTWBZNPNIC-UHFFFAOYSA-N 618-80-4 Chemical compound OC1=C(Cl)C=C([N+]([O-])=O)C=C1Cl PXSGFTWBZNPNIC-UHFFFAOYSA-N 0.000 description 1
- BOFRXDMCQRTGII-UHFFFAOYSA-N 619-08-9 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1Cl BOFRXDMCQRTGII-UHFFFAOYSA-N 0.000 description 1
- WBHYZUAQCSHXCT-UHFFFAOYSA-N 99-28-5 Chemical compound OC1=C(Br)C=C([N+]([O-])=O)C=C1Br WBHYZUAQCSHXCT-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- UBBCYDPSFMEFFL-DHGKCCLASA-N n-[(2s,3r,4r,5s,6r)-2-(2-chloro-4-nitrophenoxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1Cl UBBCYDPSFMEFFL-DHGKCCLASA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
(産業上の利用分野)
本発明はβ−N−アセチル−D−ヘキソサミニ
ダーゼ活性測定用試薬に関するものである。体液
中のβ−N−アセチル−D−ヘキソサミニダーゼ
活性の測定は、腎移植後の拒絶反応の早期診断、
急性腎不全、糸球体腎炎等の各種腎疾患の診断及
び経過観察、薬物の腎毒性等に有用な情報を与え
るものとして臨床的意義が高い。
(従来の技術)
従来、β−N−アセチル−D−ヘキソサミニダ
ーゼ(以下NAGと略する)活性は、N−アセチ
ル−D−グルコサミンの還元末端にp−ニトロフ
エノールを結合させた基質を用いてNAGを作用
させ、遊離してくるp−ニトロフエノールをアル
カリ性下で比色する方法が一般的である
(Methods Engymol.、28、702(1972))。
ところがこの方法では目的とする酵素NAGの
至適PH(PH4〜5.5)と発色用であるp−ニトロ
フエノールの発色PH(PH9以上)とが異なる為に
NAG活性を測定する為には酵素反応と発色反応
を別々に行なう必要があり、その為に試薬数及び
操作ステツプが多く必要となり、酵素活性を求め
る場合に一番適当であるといわれている速度分析
(レートアツセイ)法が出来ない欠点がある。
その他、N−アセチルグルコサミンにフエノー
ルを結合させた基質を用いる方法(特開昭54−
60997号)、N−アセチルグルコサミンにm−クレ
ゾールスルホフタレインを結合させた基質を用い
る方法(Clin.Chem.29、1713(1983))も上記p
−ニトロフエノールを用いる場合と同様の欠点が
ある。
(発明の解決しようとする問題点)
本発明の目的は定量性に優れたNAGのレート
アツセイが可能となるNAG活性測定試薬を提供
することである。
(問題点を解決する為の手段)
本発明者らは、上記目的を達成するために種々
鋭意検討したところ、一般色〔〕で示される基
質を用いることにより体液中のNAG活性を短時
間に正確簡単にレートアツセイ出来ることを見い
出し本発明に到達した。
すなわち本発明は基質として下記一般式〔〕
で示される化合物を含有することを特徴とするβ
−N−アセチル−D−ヘキソサミニダーゼ活性測
定試薬である。
(Industrial Application Field) The present invention relates to a reagent for measuring β-N-acetyl-D-hexosaminidase activity. Measurement of β-N-acetyl-D-hexosaminidase activity in body fluids can be used for early diagnosis of rejection after kidney transplantation,
It has great clinical significance as it provides useful information for the diagnosis and follow-up of various renal diseases such as acute renal failure and glomerulonephritis, and for the nephrotoxicity of drugs. (Prior Art) Conventionally, β-N-acetyl-D-hexosaminidase (hereinafter abbreviated as NAG) activity was achieved by using a substrate in which p-nitrophenol was bound to the reducing end of N-acetyl-D-glucosamine. A common method is to colorimetrically measure p-nitrophenol released under alkaline conditions (Methods Engymol., 28 , 702 (1972)). However, with this method, the optimum pH of the target enzyme NAG (PH4-5.5) is different from the coloring pH of p-nitrophenol (PH9 or higher), which is used for coloring.
In order to measure NAG activity, it is necessary to perform the enzymatic reaction and the coloring reaction separately, which requires a large number of reagents and a large number of operational steps. It has the disadvantage that analysis (rate assay) methods cannot be used. Other methods include a method using a substrate in which phenol is bound to N-acetylglucosamine (Japanese Patent Laid-Open No.
60997), a method using a substrate in which m-cresolsulfophthalein is bound to N-acetylglucosamine (Clin.Chem. 29 , 1713 (1983)) is also described in the above p.
- There are the same disadvantages as when using nitrophenol. (Problems to be Solved by the Invention) An object of the present invention is to provide a reagent for measuring NAG activity that enables rate assay of NAG with excellent quantitative properties. (Means for Solving the Problems) In order to achieve the above object, the present inventors conducted various intensive studies and found that NAG activity in body fluids can be reduced in a short time by using a substrate shown in general color [ ]. We have discovered that rate assay can be done accurately and easily, and have arrived at the present invention. That is, the present invention uses the following general formula [] as a substrate.
β characterized by containing a compound represented by
-N-acetyl-D-hexosaminidase activity measurement reagent.
【化】
〔式中、AはN−アセチルグルコサミン又はN−
アセチルガラクトサミン残基であつて、その還元
性末端が置換芳香族基(解裂したアグリコンとし
て基質とは異なつたスペクトル吸収を示す基)と
β−結合されている。置換芳香族基中のXはニト
ロ基または水素原子を示す。Xが水素原子の場合
はR1〜R4のいずれかの置換基の2個以上がニト
ロ基であり、他の基は水素原子又はハロゲン原子
である。Xがニトロ基の場合はR1および/また
はR4はハロゲン原子またはニトロ基を示し、残
りのR1〜R4は水素原子、ハロゲン原子またはニ
トロ基のいずれかを示す。)
本発明に用いる基質としては一般式〔〕で示
される化合物、すなわちN−アセチルグルコサミ
ン又はN−アセチルガラクトサミンとその還元性
末端で置換芳香族基とβ−結合したものである。
置換芳香族基とは解裂したアグリコンとしては基
質とは異なつたスペクトル吸収を示す置換芳香族
基であればいかなるものでも良いが、具体的には[Formula, A is N-acetylglucosamine or N-
It is an acetylgalactosamine residue whose reducing end is β-bonded with a substituted aromatic group (a group that exhibits a different spectral absorption than the substrate as a cleaved aglycone). X in the substituted aromatic group represents a nitro group or a hydrogen atom. When X is a hydrogen atom, two or more of the substituents among R 1 to R 4 are nitro groups, and the other groups are hydrogen atoms or halogen atoms. When X is a nitro group, R 1 and/or R 4 represent a halogen atom or a nitro group, and the remaining R 1 to R 4 represent either a hydrogen atom, a halogen atom, or a nitro group. ) The substrate used in the present invention is a compound represented by the general formula [ ], that is, N-acetylglucosamine or N-acetylgalactosamine and its reducing end bonded to a substituted aromatic group through a β-bond.
The substituted aromatic group may be any substituted aromatic group that exhibits a different spectral absorption from the substrate as a cleaved aglycone, but specifically,
【化】
(X、R1〜R4は前記のものと同じ)で示される。
その置換芳香族基はフエノールの形で示せば、
例えば2,6−ジクロロ−4−ニトロフエノー
ル、2,6−ジブロモ−4−ニトロフエノール、
2,3,6−トリクロロ−4−ニトロフエノー
ル、2,3,6−トリブロモ−4−ニトロフエノ
ール、2,3,5,6−テトラブロモ−4−ニト
ロフエノール、2,3,5,6−テトラクロロ−
4−ニトロフエノール、2,4−ジニトロフエノ
ール、2,5−ジニトロフエノール、2−クロロ
−4−ニトロフエノール、2−ブロモ−4−ニト
ロフエノール等があげられる。
これら基質の合成方法はN−アセチルヘキソサ
ミンをアセチル化し、このアセチル化されたN−
アセチルヘキソサミンと置換芳香族基、アグリコ
ンを結合させた後、脱アセチルすることにより合
成するか(実験化学講座第24巻第304頁、1958
年)、又はアセチル化されたN−アセチルヘキソ
サミンをハロゲン化し、次いでそのハロゲン化物
と置換芳香族基、アグリコンをエーテル結合させ
たあと、脱アセチルすることにより合成すること
が出来る(Methods in Carbohydr ate
Chemistry 、第334頁)。
基質の置換芳香族基においてR1又はR4がハロ
ゲン原子である場合には、基質の溶解性の点から
見て、シクロデキストリンが必要である。
本発明に用いるシクロデキストリンとしては
α、β、γの重合度のものが知られているが、上
記基質〔〕の溶解性又は呈色のPH安定性に効果
があるものであればいかなるものでも良い。好ま
しくはα及びβ−シクロデキストリンが良い。
本発明のβ−N−アセチル−D−ヘキソサミニ
ダーゼ活性測定試薬は上記基質、シクロデキスト
リン、及び必要により塩化ナトリウムを含有す
る。
該試薬のPHは体液中のNAGの至適PHであるPH
4.0〜5.5を保つ緩衝液であれば、いかなるもので
も良い。例えばクエン酸緩衝液やその他有機酸緩
衝液、例えば酢酸、コハク酸、フタル酸等の緩衝
液があげられる。
基質濃度としては特に制限がないが、好ましく
は最大のNAGの酵素活性を示す濃度が適当であ
る。例えば1mM以上である。次にシクロデキス
トリン濃度としては基質の溶解性又は呈色のPH安
定性に有効である濃度であれば特に制限はないが
好ましくは0.1%以上が適当である。
塩化ナトリウム濃度としてはNAGの活性化に
有効な濃度であれば特に制限はないが、好ましく
は1〜1000mMが適当である。更に必要があれば
界面活性剤、防腐剤等を加えてもよい。
本発明のβ−N−アセチル−D−ヘキソサミニ
ダーゼ活性測定試薬を用いて、NAG活性を測定
する方法としては、試薬を該試薬と反応させて生
成するアグリコンの吸光度の高化を直性分光光度
計を用いて比色定量する方法である。
(発明の効果)
本発明のβ−N−アセチル−D−ヘキソサミニ
ダーゼ活性測定試薬において、一般式〔〕で示
される化合物を基質として用いることにより、体
液中のβ−N−アセチル−D−ヘキソサミニダー
ゼ活性を短時間に正確、かつ簡単にレートアツセ
イすることができる。
(実施例)
以下、本発明を実施例により詳細に説明する。
実施例 1
被検液中のNAG活性量を下記試薬を用いて下
記方法により測定した。
1 試薬
2−クロロ−4−ニトロフエニル−N−アセチ
ルβ−D−グルコサミニド 1mM
塩化ナトリウム 200mM
α−シクロデキストリン 1%
0.05Mクエン酸緩衝液(PH4.5)で全量 10ml
2 測定方法
NAG含有被検液50μに上記試薬2mlを加
えて37℃で反応させ、その吸光度を波長400n
mで測定して発色速度を求めた。
反応曲線を第1図に示す。検量波を第2図に示
す。
第1図および第2図から明らかなように、本発
明の試薬を用いると、短時間に正確かつ簡単にレ
ートアツセイすることができる。
比較例 1
1 試薬
p−ニトロフエニル−N−アセチルβ−D−グ
ルコサミニド 1mM
塩化ナトリウム 200mM
α−シクロデキストリン 1%
0.05Mクエン酸緩衝液(PH4.5)で全量
10ml
2 測定方法
実施例1と同じ方法を実施した。
反応曲線を第3図に示す。また検量線を第4図
に示す。第3図および第4図から明らかなように
p−ニトロフエニル−N−アセチルβ−D−グル
コサミニドを基質とした試薬を用いると、N−ア
セチル−D−ヘキソサミニダーゼの至適PHである
4〜5.5付近ではp−ニトロフエノールが解離し
ないため、レートアツセイができないことが判明
した。
実施例 2
1 試薬
2,6−ジクロロ−4−ニトロフエニル−N−
アセチルβ−D−グルコサミニド 1mM
塩化ナトリウム 200mM
α−シクロデキストリン 1%
0.05Mクエン酸緩衝液(PH4.5)で全量 10ml
2 測定方法
実施例1と同じ。
反応曲線を第5図に示す。また検量線を第6図
に示す。第5図および第6図から明らかなよう
に、本発明の試薬を用いると、短時間に正確かつ
簡単にレートアツセイすることができる。It is represented by: (X, R 1 to R 4 are the same as above). If the substituted aromatic group is shown in the form of phenol,
For example, 2,6-dichloro-4-nitrophenol, 2,6-dibromo-4-nitrophenol,
2,3,6-trichloro-4-nitrophenol, 2,3,6-tribromo-4-nitrophenol, 2,3,5,6-tetrabromo-4-nitrophenol, 2,3,5,6-tetra Chloro
Examples include 4-nitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2-chloro-4-nitrophenol, 2-bromo-4-nitrophenol, and the like. The method for synthesizing these substrates is to acetylate N-acetylhexosamine, and this acetylated N-
Can it be synthesized by combining acetylhexosamine with a substituted aromatic group or aglycone and then deacetylating it? (Jikken Kagaku Koza Vol. 24, p. 304, 1958
), or by halogenating acetylated N-acetylhexosamine, then linking the halide with a substituted aromatic group or aglycone to an ether bond, followed by deacetylation (Methods in Carbohydrate).
Chemistry, p. 334). When R 1 or R 4 in the substituted aromatic group of the substrate is a halogen atom, cyclodextrin is necessary from the viewpoint of solubility of the substrate. The cyclodextrins used in the present invention are known to have polymerization degrees of α, β, and γ, but any cyclodextrin may be used as long as it has an effect on the solubility of the substrate [] or the PH stability of coloration. good. α and β-cyclodextrins are preferred. The reagent for measuring β-N-acetyl-D-hexosaminidase activity of the present invention contains the above substrate, cyclodextrin, and, if necessary, sodium chloride. The pH of the reagent is the optimal pH of NAG in body fluids.
Any buffer solution that maintains the ratio between 4.0 and 5.5 may be used. Examples include citric acid buffers and other organic acid buffers, such as acetic acid, succinic acid, and phthalic acid buffers. There are no particular limitations on the substrate concentration, but a concentration that exhibits the maximum NAG enzymatic activity is preferably appropriate. For example, it is 1 mM or more. Next, the concentration of cyclodextrin is not particularly limited as long as it is effective for the solubility of the substrate or the PH stability of coloration, but it is preferably 0.1% or more. The concentration of sodium chloride is not particularly limited as long as it is effective for activating NAG, but is preferably 1 to 1000 mM. Furthermore, surfactants, preservatives, etc. may be added if necessary. A method for measuring NAG activity using the reagent for measuring β-N-acetyl-D-hexosaminidase activity of the present invention is to directly increase the absorbance of the aglycone produced by reacting the reagent with the reagent. This is a method of colorimetric determination using a spectrophotometer. (Effect of the invention) In the reagent for measuring β-N-acetyl-D-hexosaminidase activity of the present invention, by using the compound represented by the general formula [] as a substrate, β-N-acetyl-D- - Hexosaminidase activity can be accurately and easily rate assayed in a short time. (Example) Hereinafter, the present invention will be explained in detail with reference to Examples. Example 1 The amount of NAG activity in the test solution was measured using the following reagent and the following method. 1 Reagent 2-chloro-4-nitrophenyl-N-acetyl β-D-glucosaminide 1mM Sodium chloride 200mM α-cyclodextrin 1% 0.05M citric acid buffer (PH4.5) total volume 10ml 2 Measurement method NAG-containing test solution Add 2 ml of the above reagent to 50μ, react at 37℃, and measure the absorbance at a wavelength of 400n.
The color development rate was determined by measuring in m. The reaction curve is shown in FIG. The calibration wave is shown in Figure 2. As is clear from FIGS. 1 and 2, rate assays can be performed accurately and easily in a short period of time using the reagents of the present invention. Comparative Example 1 1 Reagent p-nitrophenyl-N-acetyl β-D-glucosaminide 1mM Sodium chloride 200mM α-cyclodextrin 1% 0.05M citrate buffer (PH4.5) total volume 10ml 2 Measurement method Same method as Example 1 was carried out. The reaction curve is shown in FIG. Moreover, the calibration curve is shown in FIG. As is clear from FIGS. 3 and 4, when using a reagent with p-nitrophenyl-N-acetyl β-D-glucosaminid as a substrate, the optimal pH for N-acetyl-D-hexosaminidase is 4. It was found that rate assay was not possible at around ~5.5 because p-nitrophenol did not dissociate. Example 2 1 Reagent 2,6-dichloro-4-nitrophenyl-N-
Acetyl β-D-glucosaminide 1mM Sodium chloride 200mM α-cyclodextrin 1% 0.05M citrate buffer (PH4.5) total volume 10ml 2 Measurement method Same as Example 1. The reaction curve is shown in FIG. Further, a calibration curve is shown in FIG. As is clear from FIGS. 5 and 6, rate assays can be performed accurately and easily in a short period of time using the reagents of the present invention.
第1図は本発明実施例1の反応曲線を示す。第
2図は本発明実施例1の検量線を示す。第3図は
本発明比較例1の反応曲線を示す。第4図は本発
明比較例1の検量線を示す。第5図は本発明実施
例2の反応曲線を示す。第6図は本発明実施例2
の検量線を示す。
FIG. 1 shows the reaction curve of Example 1 of the present invention. FIG. 2 shows the calibration curve of Example 1 of the present invention. FIG. 3 shows the reaction curve of Comparative Example 1 of the present invention. FIG. 4 shows the calibration curve of Comparative Example 1 of the present invention. FIG. 5 shows the reaction curve of Example 2 of the present invention. Fig. 6 shows the second embodiment of the present invention.
The calibration curve is shown.
Claims (1)
物およびシクロデキストリンを含有することを特
徴とするβ−N−アセチル−D−ヘキソサミニダ
ーゼ活性測定試薬。 【化】 〔式中、AはN−アセチルグルコサミン又はN−
アセチルガラクトサミン残基であつて、その還元
性末端が置換芳香族基(解裂したアグリコンとし
て基質とは異なつたスペクトル吸収を示す基)と
β−結合されている。置換芳香族基中のXはニト
ロ基または水素原子を示す。Xが水素原子の場合
はR1〜R4のいずれかの置換基の2個以上がニト
ロ基であり、他の基は水素原子又はハロゲン原子
である。Xがニトロ基の場合はR1および/また
はR4はハロゲン原子またはニトロ基を示し、残
りのR1〜R4は水素原子、ハロゲン原子またはニ
トロ基のいずれかを示す。〕[Scope of Claims] 1. A reagent for measuring β-N-acetyl-D-hexosaminidase activity, which contains a compound represented by the following general formula [] and cyclodextrin as substrates. [Formula, A is N-acetylglucosamine or N-
It is an acetylgalactosamine residue whose reducing end is β-bonded with a substituted aromatic group (a group that exhibits a different spectral absorption than the substrate as a cleaved aglycone). X in the substituted aromatic group represents a nitro group or a hydrogen atom. When X is a hydrogen atom, two or more of the substituents among R 1 to R 4 are nitro groups, and the other groups are hydrogen atoms or halogen atoms. When X is a nitro group, R 1 and/or R 4 represent a halogen atom or a nitro group, and the remaining R 1 to R 4 represent either a hydrogen atom, a halogen atom, or a nitro group. ]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1745285A JPS61177999A (en) | 1985-01-30 | 1985-01-30 | Measuring reagent for beta-n-acetyl-d-hexosaminidase activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1745285A JPS61177999A (en) | 1985-01-30 | 1985-01-30 | Measuring reagent for beta-n-acetyl-d-hexosaminidase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61177999A JPS61177999A (en) | 1986-08-09 |
| JPH0573398B2 true JPH0573398B2 (en) | 1993-10-14 |
Family
ID=11944412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1745285A Granted JPS61177999A (en) | 1985-01-30 | 1985-01-30 | Measuring reagent for beta-n-acetyl-d-hexosaminidase activity |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61177999A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69023710T2 (en) * | 1989-02-23 | 1996-04-18 | Iatron Lab | METHOD FOR DETERMINING ENZYMATIC EFFECTIVENESS. |
-
1985
- 1985-01-30 JP JP1745285A patent/JPS61177999A/en active Granted
Non-Patent Citations (2)
| Title |
|---|
| BIOCHEMICAL PLEPARATIONS=1963 * |
| METHODS ENZYMOL=1972 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61177999A (en) | 1986-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4233403A (en) | Amylase assay | |
| JPS58501357A (en) | Enzyme analysis method for biological fluids | |
| EP0180961B1 (en) | Glucosamine derivatives and reagent for assaying n-acetyl-beta-d-glucosaminidase using the same as substrate | |
| JPH0573398B2 (en) | ||
| JPS59104556A (en) | Protein stabilizing agent | |
| US5126329A (en) | Glucosamine derivatives and compositions reagents and containing the same | |
| JPH0559083A (en) | Novel N-acetyl-β-D-glucosamine derivative and N-acetyl-β-D-glucosaminidase activity measuring method using the same as a substrate | |
| EP0260414B1 (en) | Method of differential assay for alpha-amylase isozymes and a kit for the same | |
| EP0411159A1 (en) | Method for determining enzymatic activity | |
| JPH03206896A (en) | Determination of very small amount component in body fluid | |
| JPH0542273B2 (en) | ||
| JPS6296099A (en) | Reagent for determination of acidic phosphatase activity | |
| JPH0611239B2 (en) | Reagent for measuring β-N-acetyl-D-hexosaminidase activity | |
| JPS63214193A (en) | Production of 6-glucosylmaltooligosaccharide derivative and measurement of alpha-amylase activity using said derivative | |
| JPH0113840B2 (en) | ||
| US5350677A (en) | Method of assaying phosphatase with 3,4-dinitrophenylphosphate | |
| JPH0555517B2 (en) | ||
| JP2007228896A (en) | Method for measuring hyaluronic acid | |
| JP3266967B2 (en) | Novel oligosaccharide derivative, method for producing the same, and method for measuring α-amylase activity using the same as a substrate | |
| AU621858B2 (en) | Calcium assay reagent | |
| JPS62138199A (en) | Reagent for determining alpha-amylase activity | |
| JPH04100801A (en) | Cyclodextrin derivative and color development by using same | |
| JPH0631292B2 (en) | N-acetyl-β-D-hexosamine derivative and N-acetyl-β-D-hexosaminidase activity measuring reagent using the derivative as a substrate | |
| JPS62175198A (en) | Reagent for measuring allylsulfatase activity | |
| JPS6317895A (en) | Novel oligosaccharide derivative and determination of alpha-amylase activity using same |